Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, has received $1.5 million in R&D Tax Incentives from the Australian Tax Office for FY19.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product.
Anatara Lifesciences Ltd's (ASX:ANR) lead human health product, GaRP, is being developed to specifically target two human gastrointestinal (GI) disorders, Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet medical need.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its financial results for the financial year ended 30 June 2019 (FY2019).
Global technology company Zoono Group Limited (ASX:ZNO) is pleased to announce that it has signed a new sales and distribution agreement in China. The agreement is with Guangzhou Sanchengyun Trade Co., Ltd for the sale of Zoono branded products online in China.
Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore recently spoke with experienced business writer, Tim Boreham, for his Dr Boreham's Crucible column which was published in Biotech Daily on Friday night and then reproduced in Stockhead across the weekend.
The 2018-2019 year has been a year of transition for Anatara Lifesciences (ASX:ANR), having commenced the year with a clear focus on successfully evolving into a human health company, through the pursuit of the burgeoning gastrointestinal health market.
